193 related articles for article (PubMed ID: 9690666)
21. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
22. [The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].
Song Y; Wu G; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1453-6. PubMed ID: 15733464
[TBL] [Abstract][Full Text] [Related]
23. [Neuroendocrine features of prostatic tumors: state of the art].
Turitto G; Frattolillo A; Iodice P; Auriemma A; Tortoriello A; di Grazia M; Iaffaioli RV
Recenti Prog Med; 2003 Dec; 94(12):568-72. PubMed ID: 14974154
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities.
Vashchenko N; Abrahamsson PA
Eur Urol; 2005 Feb; 47(2):147-55. PubMed ID: 15661408
[TBL] [Abstract][Full Text] [Related]
25. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate.
Dema A; Raica M; Tudose N
Rom J Morphol Embryol; 1996; 42(1-2):83-8. PubMed ID: 9038390
[TBL] [Abstract][Full Text] [Related]
28. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism.
Sainz RM; Mayo JC; Tan DX; León J; Manchester L; Reiter RJ
Prostate; 2005 Apr; 63(1):29-43. PubMed ID: 15378522
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine pathogenesis in adenocarcinoma of the prostate.
Hansson J; Abrahamsson PA
Ann Oncol; 2001; 12 Suppl 2():S145-52. PubMed ID: 11762343
[TBL] [Abstract][Full Text] [Related]
30. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine differentiation in prostate cancer.
Shariff AH; Ather MH
Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
[No Abstract] [Full Text] [Related]
32. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments.
di Sant'Agnese PA
Ann Oncol; 2001; 12 Suppl 2():S135-40. PubMed ID: 11762341
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
36. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
37. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype.
Evangelou AI; Winter SF; Huss WJ; Bok RA; Greenberg NM
J Cell Biochem; 2004 Mar; 91(4):671-83. PubMed ID: 14991759
[TBL] [Abstract][Full Text] [Related]
38. Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells.
Deeble PD; Cox ME; Frierson HF; Sikes RA; Palmer JB; Davidson RJ; Casarez EV; Amorino GP; Parsons SJ
Cancer Res; 2007 Apr; 67(8):3663-72. PubMed ID: 17440078
[TBL] [Abstract][Full Text] [Related]
39. Unusual prostate carcinoma characterized by extensive metastasis, significantly increased serum level of prostatic-specific antigen,and neuroendocrine differentiation: a case report.
Hu YX; Ye J; Jiang Y; Zhang QF; Wu YL; Chen YY
Chin Med J (Engl); 2005 Feb; 118(3):258-61. PubMed ID: 15740661
[No Abstract] [Full Text] [Related]
40. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
